Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
Globus Medical Inc (GMED)
Q2 2013 Results Earnings Call
August 1, 2013 5:30 PM ET
David Paul - Chairman and CEO
Dave Demski - President and COO
Richard Baron - Senior Vice President, Finance and CFO
Ed Joyce - Investor Relations, Director
Bob Hopkins - Bank of America
Matt Miksic - Piper Jaffray
Bill Plovanic - Canaccord Genuity
David Roman - Goldman Sachs
Richard Newitter - Leerink Swann
Steven Lichtman - Oppenheimer
» Globus Medical's CEO Discusses Q4 2012 Results - Earnings Call Transcript
» Emeritus Management Discusses Q2 2013 Results - Earnings Call Transcript
I will now turn the call over to Ed.
Thank you and thanks for being with us today. I will now read our required legal disclaimers.
During this call, items may be discussed that are not based entirely on historical facts. These items should be considered forward-looking statements and are subject to many risks, uncertainties, and other factors that are difficult to predict and may affect our business and operations. As a result, our actual results may differ materially and adversely from those expressed or implied by our forward-looking statements.
As discussed -- a discussion of some of these risks, uncertainties, and other factors are set forth in our Form’s 10-Q and 10-K on filed with the SEC. These documents are available at www.sec.com.
We take no obligation and do not intend to update any forward-looking statements as a result of new information, future events or circumstances arising after the date on which it was made.
The financial information discussed in connection with this call reflects estimates based on information available at this time and could differ materially from the amounts ultimately reported in our second quarter 2013 Form 10-Q.
Our revenue, earnings, operating margins and similar items are sometimes expressed on a non-GAAP basis and have been adjusted to include certain items including among other things interest expense, depreciation, amortization, taxes, provision for litigation loss or income, and stock-based compensation.
The comparable GAAP financial information and a reconciliation of non-GAAP amounts to GAAP amount can be find -- found in the tables included in today’s earnings release, which is available on the Globus Medical Investor Relations website at www.globusmedical.com.
I will now turn the call over to Dave Demski, President and COO.
Thanks, Ed, and welcome to everyone on the call. I will provide a commentary on our overall performance for the quarter, Rick will give some additional color on our financials, and then David Paul will provide some insight into our product development efforts.
We had record breaking sales in the second quarter and the first half of 2013. We continue to execute on our three-prong strategy of technology innovation, expanding our sales force footprint both domestically and OUS, and maintaining financial discipline and operating efficiency.
Second quarter sales were record $107 million, 11.5% higher than Q2 2012. Not only this growth rate outstanding in comparison to our peers it is compared to a very strong Q2 in 2012 in which we grew 18.6%.
Adjusted EBITDA of 34% compares to 36.1% in Q2 2012. A reduction of 2.1 percentage points, in line with expectation as 1.6 percentage points of this delta is attributable to the medical device excise tax.
As previously announced, the jury trial with DePuy Synthes concerning our plate spacer technology concluded on June 14th with the decision in favor of DePuy Synthes. We had reserved a total of $19.5 million in the second quarter to cover potential damages and cost associate with lawsuit.
While we are not happy with the result and intend to appeal, we do have clarity on the magnitude of the liability and result does not impact future revenues as improved versions of all three products were launched in late 2012.
We continue to launch a steady stream of new technology. In Q2 we launched six new products including LATIS, a unique laterally expanding interbody device that David will discuss in his remarks. Our pipeline of future products is significant with some exciting second half launches anticipated.
Sales force recruiting continued to have robust pace in the second quarter. While we don’t really specific headcount numbers our net U.S. additions in the first half of 2013 surpassed the full year net additions in the U.S. for every year since 2007. Not only has the quantity of recruits been excellent, the quality of experienced sales professional has been exceptional.
As we have discussed in the past, the impact of recruiting on sales tends to be modest in the first 12 months after hire. With a more pronounced ramp in the second year due to non-compete restrictions.
The large uptick in the first half hiring could result in slight drag on EBITDA percentage over the last half of this year, but it should not be a material. We are excited about the potential impact of our first half efforts in this area and expect to see positive sale momentum over the next 18 to 24 months.
Revenue from international operations grew 20.3% in Q2 over the comparable period last year. Between 2010 and 2011, we grew our OUS footprint from five to 24 countries. Much of our efforts during the first half of 2013 were focused on improving the efficiency of our OUS operations and getting that segment of the business EBITDA positive.